Netherlands-based pharmaceutical company Code Pharma is poised to make a significant impact in the fight against HIV with their groundbreaking drug, GAMMORA. The company has announced that they will be presenting their promising clinical trial results at two prestigious events this year.
The first presentation will take place in November 2024 at the HIV Drug Therapy 2024 Conference in Glasgow, Scotland. Code Pharma will unveil early-stage results from their clinical trials, highlighting GAMMORA’s unique approach and its potential to revolutionize HIV treatment.
In December 2024, the company will shift their focus to the HIV Persistence During Therapy Workshop in Miami, Florida. This event will showcase GAMMORA’s potential to target and eliminate HIV-infected cells in ways not seen in current therapies.
GAMMORA, developed by Code Pharma, takes a novel approach to treating HIV by inducing the self-destruction of infected cells. Unlike traditional antiretroviral therapies, which focus on controlling the virus, GAMMORA’s precision targeting ensures that only infected cells are eliminated, leaving healthy cells intact. This breakthrough drug has shown promising results in early clinical trials, reducing viral load without harmful side effects.
Code Pharma is a leading global pharmaceutical company with R&D operations in Israel. Specializing in the development of cost-effective, peptide-based treatments for infectious diseases and cancer, Code Pharma collaborates with international experts to deliver groundbreaking therapies that address unmet medical needs. Their ultimate goal is to transform patient outcomes worldwide.
For more information about Code Pharma, GAMMORA, or upcoming events, visit their website at https://www.codepharma.com/ or email them at info@codepharma.com.
This news has been distributed by Pressat, a leading UK press release distribution service.
